[go: up one dir, main page]

WO1999012545A3 - Medicaments contenant acyclovir - Google Patents

Medicaments contenant acyclovir Download PDF

Info

Publication number
WO1999012545A3
WO1999012545A3 PCT/EP1998/005560 EP9805560W WO9912545A3 WO 1999012545 A3 WO1999012545 A3 WO 1999012545A3 EP 9805560 W EP9805560 W EP 9805560W WO 9912545 A3 WO9912545 A3 WO 9912545A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments containing
skin
relates
containing acyclovir
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/005560
Other languages
English (en)
Other versions
WO1999012545A2 (fr
Inventor
Robin Currie
Mickey Lee Wells
Sandra Kay Olive Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU97408/98A priority Critical patent/AU9740898A/en
Publication of WO1999012545A2 publication Critical patent/WO1999012545A2/fr
Publication of WO1999012545A3 publication Critical patent/WO1999012545A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formulation pharmaceutique topique servant à traiter des infections virales de la peau et des muqueuses et, en particulier, des formulations topiques de gel aqueux contenant 9-(2-hydroxyéthoxyméthyl)guanine, connue sous le non d'aciclovir, présentant la stabilité requise et permettant au composé de s'écouler vers l'intérieur de la peau.
PCT/EP1998/005560 1997-09-05 1998-09-03 Medicaments contenant acyclovir Ceased WO1999012545A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU97408/98A AU9740898A (en) 1997-09-05 1998-09-03 Medicaments containing acyclovir

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9718791.8 1997-09-05
GBGB9718791.8A GB9718791D0 (en) 1997-09-05 1997-09-05 Medicaments

Publications (2)

Publication Number Publication Date
WO1999012545A2 WO1999012545A2 (fr) 1999-03-18
WO1999012545A3 true WO1999012545A3 (fr) 1999-06-10

Family

ID=10818545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/005560 Ceased WO1999012545A2 (fr) 1997-09-05 1998-09-03 Medicaments contenant acyclovir

Country Status (3)

Country Link
AU (1) AU9740898A (fr)
GB (1) GB9718791D0 (fr)
WO (1) WO1999012545A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9545408B2 (en) 2013-03-14 2017-01-17 Quadex Pharmaceuticals, Inc. Combined systemic and topical treatment of disordered tissues
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211243B1 (en) * 1999-09-22 2001-04-03 B. Ron Johnson Methods for treating cold sores with anti-infective compositions
AU2004202929B2 (en) * 1999-09-22 2006-11-23 B. Ron Johnson Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores
FR2837102B1 (fr) * 2002-03-18 2004-10-08 Palbian Snc Composition a l'etat de gel aqueux, procede de fabrication et utilisation pour la fabrication d'un medicament, notamment antiherpetique
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
CA2570599C (fr) * 2004-06-24 2012-03-27 Idexx Laboratories, Inc. Compositions pharmaceutiques destinees a l'administration medicamenteuse et methodes de traitement ou de prevention d'etats au moyen de celles-ci
US8771712B2 (en) * 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
JP4972062B2 (ja) * 2008-03-17 2012-07-11 メディヴィル・アクチエボラーグ 抗ウイルス製剤
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
US8846725B2 (en) 2011-01-24 2014-09-30 Quadex Pharmaceuticals, Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
JP2022538782A (ja) * 2019-06-14 2022-09-06 プロペラ セラピューティクス インコーポレイテッド 局所用アシクロビル製剤およびその使用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044543A1 (fr) * 1980-07-18 1982-01-27 The Wellcome Foundation Limited Formulations topiques à base de 9(2-hydroxyéthoxyméthyl) guanine
EP0551626A1 (fr) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Gel thermoréversible utile comme excipient pharmaceutique pour une formation galénique
EP0614659A2 (fr) * 1993-03-11 1994-09-14 Taro Pharmaceutical Industries Limited Compositions pharmaceutiques semi-solides et un dispositif pour l'administration de ces compositions
EP0679390A2 (fr) * 1994-04-29 1995-11-02 Zyma SA Préparations pharmaceutiques vaporisables pour l'application topique
DE4425322A1 (de) * 1994-07-18 1996-01-25 Merck Patent Gmbh Virostatika in hydrophober Gelgrundlage
EP0733357A1 (fr) * 1995-03-22 1996-09-25 Dompé S.P.A. Compositions pharmaceutiques sous forme de gel thixotropique
WO1997034607A1 (fr) * 1996-03-20 1997-09-25 Glaxo Group Limited Formulations d'aciclovir a usage local

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044543A1 (fr) * 1980-07-18 1982-01-27 The Wellcome Foundation Limited Formulations topiques à base de 9(2-hydroxyéthoxyméthyl) guanine
EP0551626A1 (fr) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Gel thermoréversible utile comme excipient pharmaceutique pour une formation galénique
EP0614659A2 (fr) * 1993-03-11 1994-09-14 Taro Pharmaceutical Industries Limited Compositions pharmaceutiques semi-solides et un dispositif pour l'administration de ces compositions
EP0679390A2 (fr) * 1994-04-29 1995-11-02 Zyma SA Préparations pharmaceutiques vaporisables pour l'application topique
DE4425322A1 (de) * 1994-07-18 1996-01-25 Merck Patent Gmbh Virostatika in hydrophober Gelgrundlage
EP0733357A1 (fr) * 1995-03-22 1996-09-25 Dompé S.P.A. Compositions pharmaceutiques sous forme de gel thixotropique
WO1997034607A1 (fr) * 1996-03-20 1997-09-25 Glaxo Group Limited Formulations d'aciclovir a usage local

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9545408B2 (en) 2013-03-14 2017-01-17 Quadex Pharmaceuticals, Inc. Combined systemic and topical treatment of disordered tissues
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue

Also Published As

Publication number Publication date
WO1999012545A2 (fr) 1999-03-18
GB9718791D0 (en) 1997-11-12
AU9740898A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
WO1999012545A3 (fr) Medicaments contenant acyclovir
CA2293470A1 (fr) Derives de benzimidazole
WO1998024436A3 (fr) Formulations sous forme de gel pour l'administration locale de medicaments
BR9712610A (pt) Composições farmacêutica e liquida, uso de aciclovir ou de um derivado do mesmo farmaceuticamente aceitável, processo para preparação de uma composição, e, disportivo de aplicação tópica.
IE811617L (en) Topical formulations of 9-(2-hydroxyethoxymethyl) guanine
ATE163980T1 (de) Antivirale topische pharmazeutische zusammensetzungen
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
CA2211802A1 (fr) Composition pharmaceutique pour le traitement de l'herpes
AU2108500A (en) Galenic formulation containing biotin
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
EP0351215A3 (fr) Ester de 9-(2-hydroxyéthoxyméthyl)guanine
WO2002000208A3 (fr) Preparations de derives d'acide 3-n-formylhydroxylaminopropylphosphonique ou de derives d'acide 3-n-acetylhydroxylaminopropylphosphonique combines avec des principes actifs pharmaceutiques speciaux
WO2002036067A3 (fr) Derives de cytokine de longue action et compositions pharmaceutiques comprenant ces derives
AU4040195A (en) Topical composition containing penciclovir
CA2074503A1 (fr) Formulation pharmaceutique contenant du penciclovir
EP0341661A3 (fr) Association d'un peptide et d'un médicament contenant un derivé de l'acide alpha-amino boronique
HK1039275A1 (zh) 含有二甲聚硅氧烷的阿昔洛韋組合物
AU2001274000A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
EP1523976A3 (fr) Formulations pharmaceutiques de salméterol
AU2001282410A1 (en) N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
AU2000267375A1 (en) Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
AU2001242819A1 (en) Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof
CA2244268A1 (fr) Analogues de nucleosides utilises dans une therapie combinee contre des infections dues a l'herpes simplex
AU2002355691A1 (en) Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
IT1273460B (it) Formulazioni farmaceutiche ad azione antivirale per uso topico

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA